PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study

Alison J. Moskowitz, Heiko Schöder, Joachim Yahalom, Susan J. McCall, Stephanie Y. Fox, John Gerecitano, Ravinder Grewal, Paul A. Hamlin, Steven Horwitz, Rachel Kobos, Anita Kumar, Matthew Matasar, Ariela Noy, M. Lia Palomba, Miguel Angel Perales, Carol S. Portlock, Craig Sauter, Neerav Shukla, Peter Steinherz, David StrausTanya Trippett, Anas Younes, Andrew Zelenetz, Craig Moskowitz

Research output: Contribution to journalArticle

126 Scopus citations

Fingerprint Dive into the research topics of 'PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences